Physician profile
Anas Karaman
NPI 1407388325
$1,043.31
in general payments reported to CMS, 2019-2025
13 companies · $336 in 2025
The $336 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.90 · 2020: $17.39 · 2021: $114 · 2022: $116 · 2024: $446 · 2025: $336.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $782.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $782.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $190.47 | 2024 | Artiss, Ips - Oncology |
| Novo Nordisk INC | $185.16 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $129.46 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $120.83 | 2021-2024 | Farxiga, Airsupra |
| Astellas Pharma US INC | $99.99 | 2022 | |
| Amgen INC. | $75.36 | 2020-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $73.93 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.80 | 2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $40.91 | 2021-2025 | Zoryve |
| Lilly USA, LLC | $32.46 | 2022-2025 | Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.14 | 2025 | Jardiance |
| Exact Sciences Corporation | $16.37 | 2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $15.43 | 2025 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anas Karaman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.